Open AccessIsocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi‐specific monoclonal antibody MsMab‐1
Author(s) -
Liu Xing,
Kato Yukinari,
Kaneko Mika Kato,
Sugawara Masato,
Ogasawara Satoshi,
Tsujimoto Yuta,
Naganuma Yasushi,
Yamakawa Mitsunori,
Tsuchiya Takashi,
Takagi Michiaki
Publication year - 2013
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.149
Subject(s) - isocitrate dehydrogenase , osteosarcoma , microbiology and biotechnology , immunohistochemistry , biology , monoclonal antibody , mutation , idh1 , cancer research , pathology , antibody , enzyme , medicine , gene , genetics , immunology , biochemistry
Somatic mutations of isocitrate dehydrogenase ( IDH ) 1 and IDH 2 occur in gliomas, acute myeloid leukemia, and cartilaginous tumors. Somatic mosaic IDH 1/2 mutations are also reported in Ollier disease and Maffucci syndrome, which are characterized by multiple central cartilaginous tumors. Although IDH 1/2 mutation analysis against osteosarcoma has been performed in several studies, no IDH 1/2 mutation has been reported. Herein, we newly report the IDH 2‐R172S mutation in three of 12 (25%) osteosarcoma patients, which was detected by direct DNA sequencing. No monoclonal antibody (mAb) has been reported against IDH 2‐R172S mutation. However, we demonstrate that the IDH 2‐R172S peptide was recognized by our established multi‐specific anti‐mutated IDH 1/2 mAb, MsMab‐1, in enzyme‐linked immunosorbent assay. Western blot analysis revealed that MsMab‐1 reacts with PA tag combined recombinant proteins of IDH 2‐R172S. Furthermore, MsMab‐1 stained IDH 2‐R172S‐expressing osteosarcoma tissues in immunohistochemistry. The MsMab‐1 stained nine of 32 (28.1%) osteosarcomas in a tissue microarray. This report is the first describing IDH 2 mutations in osteosarcoma, which can be detected by MsMab‐1 mAb. Taken together, these results show that MsMab‐1 can be anticipated for use in immunohistochemical determination of IDH 1/2 mutation‐bearing osteosarcoma.